Perhaps reflecting the evolutionary divergence of these enzymes, the protozoan IPC synthase orthologues, from Leishmania major and T. gondii are not susceptible to AbA inhibition (Denny et al. 2006; Pratt et al. 2013). Some studies have reported the inhibitory effects of AbA and analogues against T. gondii in culture (Sonda et al. 2005; Alqaisi et al. 2017), however this is not associated with inhibition of SL biosynthesis. Despite this, the protozoan SLS's remain tractable drug targets with no functional equivalent in mammalian cells. Surprisingly, at least one SLS isoform from T. brucei was acutely sensitive to AbA treatment (Mina et al. 2009), although these findings stirred some controversy due, in part, to the redundancy of T. brucei SLSs (4 isoforms) compared with the single copy found, for example, in L. major and T. gondii (Sutterwala et al. 2008).